China NT Pharma Group Co (HKSE:01011) EBIT : HK$-6.74 Mil (TTM As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co EBIT?

China NT Pharma Group Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$7.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-6.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China NT Pharma Group Co's annualized ROC % for the quarter that ended in Jun. 2024 was -0.28%. China NT Pharma Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 1,791.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China NT Pharma Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -1.26%.

China NT Pharma Group Co EBIT Historical Data

The historical data trend for China NT Pharma Group Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co EBIT Chart

China NT Pharma Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-280.52

-136.54

-73.50

-11.92

-4.98

China NT Pharma Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															8.89	-20.39	9.07	-14.05	7.31

Competitive Comparison of China NT Pharma Group Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China NT Pharma Group Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

China NT Pharma Group Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-6.74 Mil.

China NT Pharma Group Co (HKSE:01011) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China NT Pharma Group Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-3.002 * ( 1 - 15.74% )	/	( (911.465	+	918.532)	/ 2 )
=	-2.5294852	/	914.9985
=	-0.28 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	359.987	-	162.552	-	( 1.663	-	max(0, 727.458	-	13.428	+	1.663	))
=	911.465

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	364.694	-	164.443	-	( 6.234	-	max(0, 733.788	-	15.507	+	6.234	))
=	918.532

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

China NT Pharma Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	14.62	/	( ( (1.033 + max(-342.937, 0))	+	(0.599 + max(-347.834, 0)) )	/	2 )
=	14.62	/	( ( 1.033	+	0.599 )	/	2 )
=	14.62	/	0.816
=	1,791.67 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(10.995	+	0	+	0.173)	-	(162.552	+	0	+	191.553)
=	-342.937

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5.908	+	0	+	0.00099999999999945)	-	(164.443	+	0	+	189.3)
=	-347.834

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China NT Pharma Group Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-6.741	/	534.833
	=	-1.26 %

China NT Pharma Group Co EBIT Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

China NT Pharma Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG

Website

http://www.ntpharma.com

China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.

Executives

Ieong Chong Mang
Golden Base Investment Limited
Wang Minzhi	2101 Beneficial owner
Shum Ning
Chin Yu
Ng Tit
Ieong Iat	2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines